Research Funding

Funding Opportunity Announcements

Browse below for Data Science Funding Opportunity Announcements.

This page last reviewed on September 14, 2018

Feed last updated: January 17 2019 2:00 pm
Title FOA Number Organization Release Date Expiration Date Purpose Search Terms
Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)

RFA-ES-18-007

NIEHS

Aug 31 2018

Dec 02 2020

The purpose of the updated ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts among fundamental (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward cross-disciplinary and/or translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement are encouraged.

Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required)

RFA-AI-18-046

NIAID

Oct 01 2018

Feb 16 2019

The purpose of this Funding Opportunity Announcement is to solicit applications for the Vaccine Treatment and Evaluation Units (VTEUs) to implement clinical site protocols (clinical research, clinical trials) for evaluating vaccines, other preventive biologics, therapeutics, diagnostics, including prognostic and predictive markers, and devices for the treatment and prevention of infectious diseases as part of NIAID Infectious Diseases Clinical Research Consortium (IDCRC). A companion FOA solicits applications for the Leadership Group for the Infectious Diseases Clinical Research Consortium, hereafter referred to as the Leadership Group (LG), which provides for overall administrative and scientific leadership for the clinical research and clinical trials conducted. While the primary scientific focus will be on product evaluation for NIAID priority areas, including malaria/neglected tropical diseases, sexually transmitted infections, respiratory infections, and enteric diseases, the VTEUs must also provide surge capacity to address emerging infectious diseases.

data science, big data, computational, quantitative science, informatics, bioinformatics
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

PAR-18-913

NCI

Sep 07 2018

Aug 12 2021

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

PA-18-935

NIH

Oct 03 2018

Jan 25 2022

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.

data science, big data, computational, quantitative science, informatics, bioinformatics
Understanding the Glycemic Profile of Pregnancy - Clinical Centers (U01 Clinical Trial Not Allowed)

RFA-DK-18-018

NIDDK

Oct 11 2018

Mar 27 2019

This FOA invites applications for Clinical Centers to carefully characterize the normal course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. Clinical Centers will recruit and study pregnant women starting in the first trimester and continuing at least through delivery. A separate FOA (RFA-DK-18-019) will solicit a Biostatistics Research Center. Each Clinical Center applicant will propose a study design and provide detailed information about recruitment capacity. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

data science, big data, computational, quantitative science, informatics, bioinformatics
Understanding the Glycemic Profile of Pregnancy - Biostatistics Research Center (U01 Clinical Trial Not Allowed)

RFA-DK-18-019

NIDDK

Oct 11 2018

Mar 27 2019

This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to carefully characterize the course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. A separate FOA (RFA-DK-18-018) invites Clinical Centers to recruit and study pregnant women starting in the first trimester, and continuing at least through delivery. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

data science, big data, computational, quantitative science, informatics, bioinformatics
U.S. - India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed)

PAR-18-912

NEI

Sep 07 2018

Nov 10 2020

This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications.
Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research maybe proposed. Clinical trials will not be supported under this FOA.

Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)

PAR-18-854

NIDDK

Jul 12 2018

Sep 11 2021

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)

RFA-CA-19-002

NCI

Sep 17 2018

Feb 23 2019

The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.

Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

PAR-18-514

NIA

Dec 20 2017

Jan 06 2021

This funding opportunity (FOA) encourages small business-based (STTR) research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.

Pages

XLS